2021 Fiscal Year Final Research Report
Pyridoxamine could be a candidate drug for Parkinson`s disease: Mechanistic study to reduce dopamine-induced toxicity
| Project/Area Number |
19K07187
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Lee Seon Hwa 東北大学, 薬学研究科, 准教授 (60519776)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大江 知行 東北大学, 薬学研究科, 教授 (10203712)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | Pyridoxamine / Dopamine / Parkinson`s disease / Oxidative stress |
|---|
| Outline of Final Research Achievements |
The cytotoxic effects of dopamine (DA) involve its oxidation to DA o-quinone (DAQ), which has profound implications in Parkinson’s disease (PD). Pyridoxamine (PM) is a drug candidate for diabetic complications because of its scavenging effects against reactive oxygen/carbonyl species. PM can also inhibit lipid hydroperoxide-derived protein damage by trapping lipid-derived aldehydes. In the reaction of DA and PM, pyridoxal (PL)+DA－H2O was produced. Its structure was characterized, and the reaction mechanism was proposed as follows: DA initially oxidizes to DAQ, which reacts with PM to produce PL after hydrolysis. PL then reacts with DA to form PL-DA adduct. PM was shown to scavenge DAQ in the presence of tyrosinase and glutathione. PM also inhibited DA-induced alpha-synuclein (Syn) oxidation. Therefore, PM could prevent DA-induced dopaminergic cell death and aggregation of Syn involved in PD, and the resulting PL-DA adduct can be used as a dosimeter for oxidative stress/DA oxidation.
|
| Free Research Field |
Clinical analytical chemistry, Chemical toxicology
|
| Academic Significance and Societal Importance of the Research Achievements |
今回、神経毒性化合物のDA酸化体（DAQ）とPMの反応機構、反応生成物、およびは細胞内環境に近い条件でのDAQ捕捉、α-シヌクレイン酸化阻害効果を精査した。これらの知見からPMは、糖尿病、酸化・脂質化の関与する様々な慢性疾患（高脂血症、老化など）のみならず、PD予防薬としての可能性が示された。本研究の進展により、PD予防法の確立、長期的なDA補充療法に伴う問題 (ウェアリング・オフ現象やジスキネジアの発生) の解決、ドラッグデザインへの応用等が期待される。
|
